BioCryst Pharmaceuticals BCRX Loss on lease termination
Loss on lease termination at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LossOnContractTermination.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's loss on lease termination.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's loss on lease termination?
- BioCryst Pharmaceuticals (BCRX) reported loss on lease termination of $110K in Q4 2023.
- What does loss on lease termination mean?
- This metric captures the financial impact of terminating a contractual agreement before its scheduled expiration. It typically includes penalties, write-offs of related assets, or settlement costs incurred to exit the arrangement. High values may indicate operational restructuring or a strategic shift in business partnerships.